CJC-1295 for beginners: what it is and how it's used

Last updated 2026-07-30

What is CJC-1295 and how does it work?

CJC-1295 is a lab-made peptide built to mimic growth-hormone-releasing hormone (GHRH), the signal your hypothalamus sends to the pituitary gland to release growth hormone. It binds the GHRH receptor on pituitary cells and, in animal and early human pharmacology studies, increases both the amount of growth hormone released per pulse and how long GH stays elevated in blood ^[1]. The original molecule was described in a 2005 study led by researchers who modified native GHRH (1-29) with amino acid substitutions to resist enzymatic breakdown, then attached a fatty acid chain (the "Drug Affinity Complex," or DAC) that lets the peptide bind to circulating albumin. That albumin binding is what stretches its half-life from minutes to days ^[2]. It's not a growth hormone itself. It doesn't put GH directly into your bloodstream the way injectable somatropin does. It works upstream, telling your own pituitary to make and release more of its own GH, which means the ceiling on effect depends on how much GH-producing capacity you have left. That's a meaningful difference from HGH therapy, and it's part of why the risk profile and the marketing claims diverge so much. None of this is approved for human therapeutic use in the United States. The FDA has not approved CJC-1295 for any indication, and it is commonly sold under a "research use only" label, which legally means it is not intended for human consumption ^[3].

What's the difference between CJC-1295 with DAC and without DAC?

This is the single most confusing thing for beginners, and it matters a lot for how you'd think about dosing. CJC-1295 with DAC is the original, patented molecule from the 2005 Teichman study, with the fatty acid tail attached. Because it binds albumin, its half-life in that study was reported around 6 to 8 days, and a single injection kept GH and IGF-1 elevated for multiple days in the trial participants ^[2]. That's the version associated with the name "CJC-1295" in its strict, original sense. CJC-1295 without DAC is a shorter peptide, technically GHRH(1-29) with the same stabilizing amino acid substitutions but no fatty acid tail. It's often sold under the name Mod GRF 1-29. Its half-life is short, on the order of 30 minutes or less, which means it produces a sharper, more GH-pulse-like release closer to the body's natural pattern, rather than a sustained plateau ^[4]. Here's the practical tradeoff people argue about on forums, stripped of hype: | Feature | CJC-1295 with DAC | CJC-1295 no-DAC (Mod GRF 1-29) |

Why is CJC-1295 paired with ipamorelin?

Short answer: because they act on two different receptors, and stacking them is thought to produce a larger GH pulse than either alone. Longer answer, with the honest caveat upfront: there is no CJC-1295 plus ipamorelin published clinical trial in humans. The rationale is extrapolated from separate lines of research on GHRH analogues and on ghrelin-mimetic GH secretagogues. CJC-1295 acts on the GHRH receptor. Ipamorelin is a ghrelin-receptor agonist (a GH secretagogue) that works through a separate pathway. Older research combining GHRH with GH-releasing peptides in humans (not CJC-1295 and not ipamorelin specifically, but structurally related classes) found combined administration produced greater GH release than either compound given alone, because the two receptor systems have complementary and partly independent effects on pituitary somatotroph cells ^[6]. Ipamorelin itself was characterized in a 1998 study as a selective GH secretagogue with minimal effect on cortisol, prolactin, or appetite-hormone changes compared to older secretagogues like GHRP-6, which is the main reason it became the popular pairing choice instead of GHRP-2 or GHRP-6 ^[7]. So the pairing logic is real pharmacology, but the specific combination, at the doses commonly discussed online, has not been tested in a controlled human trial with reported outcomes. Anyone telling you the stack is "proven" to add a specific amount of lean mass or improve sleep by a specific percentage is going past the data. For a broader accounting of what's documented versus assumed, the CJC-1295 pros and cons page lays it out side by side.

How is CJC-1295 typically dosed?

There is no FDA-approved dosing because there is no FDA-approved product, so anything you read, including this, reflects what's reported in the original pharmacology study and what's commonly discussed in peptide-use communities, not an approved label. In the 2005 study of CJC-1295 with DAC, single subcutaneous doses ranging from 30 mcg/kg up to 60 mcg/kg were tested in healthy adults, and researchers found sustained elevation of GH and IGF-1 for six or more days after a single injection at the higher doses ^[2]. That's a body-weight-scaled research dose, not a flat consumer dose, and it was administered and monitored in a clinical research setting. Outside of that study, community-reported protocols for no-DAC CJC-1295 (Mod GRF 1-29) commonly describe flat doses in the range of 100 to 300 mcg per injection, given once to three times daily, often timed around fasting states or before bed, on the theory that GH pulses naturally peak during early sleep. These numbers come from user-reported practice, not clinical dosing tables, and dose-response has not been formally established for that regimen. Beginners consistently make three mistakes: starting at doses scaled for experienced users, injecting immediately after a meal (insulin and GH release don't mix well, and a fed state blunts the GH pulse), and expecting visible changes within days. If you're mapping out what a realistic early experience looks like, the CJC-1295 before and after page and the results timeline both cover what changes tend to show up first and what takes longer, or doesn't show up at all.

How is CJC-1295 injected, and what does a typical protocol look like?

It's given by subcutaneous injection, meaning a short, thin needle just under the skin, typically in the abdomen, similar to how insulin or many other peptides are injected. It is not taken orally, because peptides are broken down by digestive enzymes before they'd ever reach the bloodstream intact. A common structure discussed in peptide-use forums (again, not a clinical protocol) for no-DAC CJC-1295 paired with ipamorelin looks like: reconstitute both peptides with bacteriostatic water, draw them into the same syringe, and inject once or twice daily, usually first thing in the morning on an empty stomach and/or roughly 30 to 60 minutes before bed. Cycles of 8 to 12 weeks followed by a break are frequently mentioned, based on the same GHRH receptor down-regulation concern noted earlier, though there's no dedicated trial establishing an evidence-based cycle length for this specific peptide ^[5]. For DAC versions, the once- or twice-weekly injection interval reflects its multi-day half-life, so daily dosing would be redundant and, per the pharmacokinetics in the original study, could risk more continuous receptor stimulation than the pulsatile pattern many users are trying to preserve ^[2]. Storage matters and gets skipped in a lot of forum advice: reconstituted peptides are generally kept refrigerated and used within a defined window (commonly discussed as roughly 2 to 4 weeks) because peptide bonds degrade at room temperature and with agitation. None of this is FDA-labeled guidance since there's no approved product; it's standard peptide-handling practice.

What does the actual evidence show, versus bodybuilding forum claims?

This is where beginners get misled the most. A lot of the internet's CJC-1295 content originates on bodybuilding and biohacking forums, and it gets repeated so often it starts sounding like consensus. It isn't. What's actually been studied: the core pharmacokinetics and short-term safety of CJC-1295 with DAC in one published human study (n=around 40-some healthy adults across dose groups), showing GH and IGF-1 elevation lasting days after a single dose, with the main reported adverse effects being injection-site reactions and transient flushing ^[2]. Ipamorelin's receptor selectivity and reduced side-effect profile relative to older secretagogues has separate, older human pharmacology support ^[7]. What has NOT been studied in a published clinical trial: long-term safety over months or years, effects on body composition or athletic performance with repeated dosing, the combined CJC-1295 plus ipamorelin stack, optimal dosing for non-clinical goals like fat loss or muscle gain, and use in anyone outside a controlled research setting. Claims you'll see on forums that go beyond the data: specific fat-loss percentages, specific muscle-gain timelines, claims that it "heals joints" or reliably improves skin, and claims that cycling schedules prevent desensitization. These may reflect real anecdotal experience for some individuals, but they are not backed by the kind of controlled trial data that would let anyone state a number with confidence. If you want the more skeptical, evidence-first framing of these claims, the CJC-1295 reviews page and is CJC-1295 worth it page both separate documented effects from repeated forum lore. The honest summary a beginner should hold onto: this is real, studied pharmacology at the receptor and hormone-pulse level, sitting inside a regulatory and evidence gap at the level of "does this do what people are using it for, safely, over time." Those are two different questions, and most of the internet answers only the second one, with the confidence of the first.

What are the known side effects and safety concerns?

The published human data on CJC-1295 with DAC reported injection-site redness and pain, flushing, and in some dose groups, transient changes in blood pressure or heart rate readings, alongside the expected rise in GH and IGF-1 ^[2]. That study was short-term and closely monitored; it does not tell you what happens with repeated, unsupervised dosing over months, because that hasn't been studied. Because CJC-1295 raises GH and IGF-1, the theoretical risk profile mirrors known risks of excess GH exposure generally: water retention, joint or nerve discomfort (carpal-tunnel-like symptoms are a documented effect of GH excess in acromegaly literature), insulin sensitivity changes, and in acromegaly (a disease of chronic GH/IGF-1 excess), increased risk of cardiovascular and metabolic disease over years, according to endocrine society clinical guidance ^[8]. CJC-1295 at typical discussed doses is not causing acromegaly-level exposure, but the mechanism it works through is the same axis, which is why endocrinologists are cautious about unsupervised long-term GH-axis stimulation. Quality control is a real, practical risk separate from the pharmacology. Because CJC-1295 is sold as a research chemical rather than a regulated drug, there's no FDA oversight of purity, sterility, or accurate labeling for products bought outside a legitimate, provider-reviewed pharmacy channel ^[3]. Contamination, incorrect concentration, and bacterial growth from poor reconstitution practice are documented general risks with unregulated peptide products, not specific published findings about CJC-1295 batches, but they're a well-known concern flagged by pharmacy and compounding oversight bodies. Anyone with a personal or family history of hormone-sensitive cancer, uncontrolled diabetes, or active malignancy should treat GH-axis stimulation as a real medical question requiring a doctor's involvement, not a forum thread's.

Who should not use CJC-1295, and when should you talk to a doctor first?

If you have active cancer or a history of certain hormone-sensitive cancers, GH and IGF-1 stimulation is a legitimate medical concern, since IGF-1 signaling is implicated in some tumor growth pathways; this is why growth hormone therapy itself carries cancer-history warnings in its own prescribing guidance for approved GH products ^[8]. Pregnant or breastfeeding people, anyone with uncontrolled diabetes (GH can raise blood glucose and antagonize insulin), and anyone with untreated pituitary or thyroid disease should not be experimenting with GH secretagogues outside physician supervision. More broadly: if you're doing this without any baseline bloodwork (IGF-1, fasting glucose, lipid panel at minimum) and without a plan for follow-up labs, you're flying blind on the one thing that would actually tell you whether it's doing anything measurable, and whether it's doing so safely. A real medical provider reviewing your labs and history before and during use is the difference between an informed decision and a guess.

Is CJC-1295 legal to buy, and how should a beginner source it?

In the United States, CJC-1295 is not an FDA-approved drug, and products are typically sold labeled "for research use only, not for human consumption," which is a real legal distinction, not fine print you can ignore ^[3]. That labeling exists because the FDA has not evaluated these products for safety, purity, or efficacy in humans, and selling them for human use without that approval sits outside the normal drug approval framework under the Federal Food, Drug, and Cosmetic Act. That legal gray zone is exactly why sourcing quality varies so wildly, and it's the biggest practical risk beginners underweight, more than the peptide's pharmacology itself. A provider-reviewed pathway, where a licensed provider evaluates your history and labs and a legitimate pharmacy handles compounding and fulfillment, is a meaningfully different risk profile than an anonymous research-chemical vendor with no chain of accountability. CJC-1295 Co's provider-reviewed listings route through pharmacy partners for exactly this reason: it doesn't compound or manufacture anything itself, it connects the research and reviews to a channel with an actual accountable pharmacy on the other end. If you're weighing whether to bother at all given the cost, effort, and legal ambiguity, is CJC-1295 worth it walks through that calculation directly, and CJC-1295 success rate looks at how often reported use actually lines up with the outcomes people go in expecting.

How soon do people report results, and what should a beginner realistically expect?

Because there's no controlled trial tracking outcomes like body composition or sleep quality over months of use, everything in this section is drawn from user-reported experience and general GH-axis physiology, not a clinical results table. The hormone-level effect is fast and is the one thing with actual data behind it: the original DAC study showed measurable GH and IGF-1 elevation within the study's monitoring window after a single injection, sustained for multiple days ^[2]. That's a lab-measurable change, not a felt one. Subjectively reported changes in sleep quality are the most commonly cited early effect in user reports, often within the first one to two weeks, which lines up with GH's known role in slow-wave sleep physiology, though this hasn't been isolated and measured specifically for CJC-1295 in a sleep-lab trial. Reported changes in body composition or recovery, when they're mentioned at all, are described over 8 to 12+ week windows and confounded heavily by diet and training changes happening at the same time, which makes attributing them to the peptide alone genuinely unreliable. For a fuller, more skeptical look at what's reported at each stage and how much of it is plausibly the peptide versus everything else going on in someone's routine, CJC-1295 results timeline and CJC-1295 before and after both go section by section through the realistic timeline.

Frequently asked questions

What is CJC-1295 used for?

It's used, mostly outside approved medical settings, to stimulate the body's own growth hormone release by mimicking GHRH. It has no FDA-approved use. Its studied effect is raising GH and IGF-1 levels; claims about fat loss, muscle gain, or anti-aging benefits are extrapolated from that mechanism, not proven in dedicated trials ^[1][2][3].

What's the difference between CJC-1295 and ipamorelin?

CJC-1295 mimics GHRH and works on the GHRH receptor. Ipamorelin mimics ghrelin and works on a separate ghrelin receptor. They're often paired because the two pathways are thought to produce a bigger combined GH pulse, though the combination itself hasn't been tested in a published clinical trial ^[6][7].

Does CJC-1295 need to be cycled?

Many user protocols include an 8 to 12 week on-cycle followed by a break, based on the theory that constant GHRH receptor stimulation could desensitize the receptor over time. This is a reasonable pharmacological hypothesis discussed in review literature, but there's no dedicated long-term trial confirming an optimal cycle length for CJC-1295 specifically ^[5].

Is CJC-1295 legal in the United States?

It is not FDA-approved for human use and is typically sold labeled 'research use only, not for human consumption.' That's a real regulatory category, not marketing language, and it means quality, purity, and dosing accuracy aren't federally verified the way an approved drug's would be ^[3].

How long does CJC-1295 with DAC stay active in the body?

The original 2005 pharmacokinetic study reported a half-life of roughly 6 to 8 days for CJC-1295 with DAC, with GH and IGF-1 elevation sustained for six or more days after a single injection at higher tested doses ^[2]. That long half-life is why it's typically discussed as a once or twice weekly injection rather than daily.

What is Mod GRF 1-29 and is it the same as CJC-1295?

Mod GRF 1-29 is the common name for CJC-1295 without DAC, a shorter-acting version of the same modified GHRH(1-29) backbone without the albumin-binding fatty acid tail. Its half-life is around 30 minutes, versus roughly 6 to 8 days for the DAC version, so dosing frequency differs substantially ^[4][2].

What are the side effects of CJC-1295?

The published human study reported injection-site redness and pain, flushing, and some transient blood pressure or heart rate changes alongside the intended GH rise ^[2]. Because it stimulates the same axis involved in acromegaly, theoretical long-term concerns include water retention, joint discomfort, and altered insulin sensitivity, though long-term human data specific to CJC-1295 doesn't exist ^[8].

Can beginners take CJC-1295 without ipamorelin?

Yes. CJC-1295 alone still stimulates GH release through the GHRH receptor; ipamorelin is an addition many people use to try to amplify the pulse through a second receptor pathway, not a required pairing. Plenty of documented pharmacology (the original DAC study) tested CJC-1295 by itself ^[2].

How is CJC-1295 injected?

It's given by subcutaneous injection, typically in the abdomen, using a short thin needle similar to an insulin syringe. It cannot be taken orally because digestive enzymes would break the peptide down before it reached the bloodstream intact.

Does CJC-1295 show up on standard bloodwork?

It won't show up directly on a standard panel, but its intended effect, elevated IGF-1, will. A baseline and follow-up IGF-1 test is the most practical way to see whether it's having a measurable physiological effect, and it's a test any prescribing provider should be ordering as part of monitoring.

What dose do beginners typically start with?

There's no FDA-approved dose. The original clinical study of the DAC version tested 30 to 60 mcg/kg single doses in a monitored research setting ^[2]. Community-reported protocols for the no-DAC version commonly describe 100 to 300 mcg per injection, once to a few times daily, though this reflects user practice, not established clinical dosing.

Is CJC-1295 the same as HGH?

No. HGH (somatropin) is growth hormone itself, given directly. CJC-1295 is a GHRH analogue that signals your own pituitary to release more of your own GH. The ceiling on its effect depends on your pituitary's remaining capacity, which is a fundamentally different mechanism than injecting GH directly.

Sources

1. Endocrine Society, Growth Hormone-Releasing Hormone patient resource: GHRH signals the pituitary to release growth hormone
2. Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006: CJC-1295 with DAC pharmacokinetics, half-life, dosing, and reported adverse effects in the original human study
3. U.S. FDA, Research Use Only / Investigational New Drug framework: Products labeled research use only have not been FDA-evaluated for human use
4. National Center for Biotechnology Information, PubChem compound record for Modified GRF 1-29: Structure and short half-life characteristics of CJC-1295 without DAC (Mod GRF 1-29)
5. Sigalos & Pastuszak, Sexual Medicine Reviews, review of GH secretagogues: Theoretical receptor desensitization concern with sustained GHRH receptor stimulation
6. Corpas, Harman & Blackman, Endocrine Reviews, GHRH and GH secretagogue combination research in aging: Combined GHRH and GH-releasing peptide administration produces greater GH release than either alone
7. Raun et al., European Journal of Endocrinology, 1998, ipamorelin characterization study: Ipamorelin's selective GH-release profile with minimal cortisol/prolactin effect versus older secretagogues
8. Endocrine Society Clinical Practice Guideline, Acromegaly: Risks of chronic GH/IGF-1 excess including cardiovascular, metabolic, and joint effects